Understanding metabolic syndrome in pregnant women with HIV on specific treatments
Integrated proteomic and metabolomic biomarker profiling for understanding metabolic syndrome in pregnant women living with HIV on Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir (TLD)
This study is looking at how a specific HIV treatment called Dolutegravir affects weight gain and overall health in pregnant women with HIV, to help understand any health challenges they might face during pregnancy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11161556 on NIH RePORTER |
What this research studies
This research investigates how certain HIV treatments, specifically Dolutegravir-based regimens, affect weight gain and metabolic health in pregnant women living with HIV. By conducting a prospective cohort study across multiple sites in the US and Nigeria, the research aims to identify cases of metabolic syndrome and understand the underlying mechanisms that contribute to these health issues during pregnancy. The study will utilize established criteria to assess metabolic syndrome risk among participants, providing valuable insights into the health challenges faced by this population.
Who could benefit from this research
Good fit: Ideal candidates for this research are pregnant women living with HIV who are receiving Dolutegravir-based antiretroviral therapy.
Not a fit: Patients who are not pregnant or those not receiving Dolutegravir-based treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies that minimize weight gain and metabolic complications for pregnant women living with HIV.
How similar studies have performed: Previous research has indicated that understanding metabolic impacts of HIV treatments can lead to better health outcomes, suggesting potential success for this approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Eke, Ahizechukwu C. — Johns Hopkins University
- Study coordinator: Eke, Ahizechukwu C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.